Shukla Mrinal, Callas Peter W, Lahiri Julie A, Alef Matthew J, Keating Friederike K, Stanley Andrew C, Steinthorsson Georg, Schneider David J, Bertges Daniel J
Division of Vascular Surgery, Department of Surgery, The University of Vermont Medical Center, Burlington, VT.
Division of Epidemiology, Department of Mathematics and Statistics, The University of Vermont College of Medicine, University of Vermont, Burlington, VT.
Ann Vasc Surg. 2019 Oct;60:156-164. doi: 10.1016/j.avsg.2019.02.025. Epub 2019 May 8.
Postopertive troponin elevation may occur without typical or atypical cardiac symptoms and is associated with an increased 30-day morbidity and mortality. The objective of the study was to implement a quality improvement initiative of postoperative troponin surveillance algorithm aimed at intensifying medical management after vascular surgery.
We conducted a single-center study of postoperative troponin surveillance after vascular surgery (n = 201) at a tertiary care, academic medical center from January to December 2016. Troponin surveillance was performed on postoperative days 1-3 after carotid endarterectomy, endovascular aortic repair, infrainguinal bypass, open abdominal aortic aneurysm repair, peripheral vascular intervention, and suprainguinal bypass, regardless of cardiac symptoms. Patients with troponin I elevation (>0.034 ng/mL) were managed with a treatment algorithm which included single or dual antiplatelet (AP) agent, high-intensity statin therapy, smoking cessation consultation, and outpatient cardiology consultation and stress testing. Patients with troponin elevation ≥1.0 ng/mL received inpatient cardiology consultation. We assessed adherence to the protocol for intensification of best medical therapy defined as high-dose statin therapy, increase in AP therapy, and smoking cessation consultation according to the established algorithm.
Troponin elevation was recorded in 17% (34/201) of patients and was associated with cardiac symptoms in 8 patients (24%), while 26 (76%) patients had an asymptomatic abnormal troponin on postoperative surveillance. One patient was excluded due to death immediately after SUPRA, resulting in 200 patients. Troponin elevation ≥1.0 ng/mL occurred in 11 asymptomatic patients (5.5%). Any intensification of medical therapy was instituted in 76% of patients with elevated troponin and included high-intensity statin therapy (58%), increase in AP therapy (18%), and smoking cessation consultation (66%). Once an elevated troponin level was recognized, 52% of our patients received cardiology consultation with an increased likelihood (100%) in patients with troponin ≥1 ng/mL (P < 0.001). Adherence to outpatient stress testing was 66%. Intensification of medical therapy was not significantly different between patients with abnormal troponin values, >0.034-1.0 (n = 23) versus ≥1.0 ng/mL (n = 10); statin therapy (P = 1.0), AP (P = 0.34), and smoking cessation (P = 1.0). One-year mortality was higher in patients with postoperative troponin elevation than those with normal postoperative troponin levels (12% vs. 2.4%; P = 0.03).
Routine postoperative troponin surveillance results in intensification of statin therapy in patients with asymptomatic troponin elevation. Further study is needed to determine if this approach reduces long-term cardiovascular morbidity and mortality.
术后肌钙蛋白升高可能在无典型或非典型心脏症状的情况下出现,并且与30天发病率和死亡率增加相关。本研究的目的是实施一项术后肌钙蛋白监测算法的质量改进计划,旨在加强血管手术后的医疗管理。
我们于2016年1月至12月在一家三级医疗学术医学中心进行了一项关于血管手术后术后肌钙蛋白监测的单中心研究(n = 201)。在颈动脉内膜切除术、血管腔内主动脉修复术、腹股沟下旁路移植术、开放性腹主动脉瘤修复术、外周血管介入术和腹股沟上旁路移植术后的第1 - 3天进行肌钙蛋白监测,无论有无心脏症状。肌钙蛋白I升高(>0.034 ng/mL)的患者采用一种治疗算法进行管理,该算法包括单药或双药抗血小板(AP)治疗、高强度他汀类药物治疗、戒烟咨询以及门诊心脏科咨询和压力测试。肌钙蛋白升高≥1.0 ng/mL的患者接受住院心脏科咨询。我们根据既定算法评估了对强化最佳药物治疗方案的依从性,该方案定义为高剂量他汀类药物治疗、增加AP治疗以及戒烟咨询。
在17%(34/201)的患者中记录到肌钙蛋白升高,其中8例(24%)患者伴有心脏症状,而26例(76%)患者在术后监测时肌钙蛋白无症状异常。1例患者因在腹股沟上旁路移植术后立即死亡而被排除,最终纳入200例患者。11例无症状患者(5.5%)出现肌钙蛋白升高≥1.0 ng/mL。76%肌钙蛋白升高的患者进行了任何强化药物治疗,包括高强度他汀类药物治疗(58%)、增加AP治疗(18%)和戒烟咨询(66%)。一旦识别出肌钙蛋白水平升高,52%的患者接受了心脏科咨询,肌钙蛋白≥1 ng/mL的患者接受咨询的可能性增加(100%)(P < 0.001)。门诊压力测试的依从率为66%。肌钙蛋白值异常>0.034 - 1.0 ng/mL的患者(n = 23)与≥1.0 ng/mL的患者(n = 10)之间在强化药物治疗方面无显著差异;他汀类药物治疗(P = 1.0)、AP治疗(P = 0.34)和戒烟(P = 1.0)。术后肌钙蛋白升高的患者1年死亡率高于术后肌钙蛋白水平正常的患者(12%对2.4%;P = 0.03)。
术后常规肌钙蛋白监测可使无症状肌钙蛋白升高患者的他汀类药物治疗得到强化。需要进一步研究以确定这种方法是否能降低长期心血管发病率和死亡率。